A human primary airway microphysiological system infected with SARS-CoV-2 distinguishes the treatment efficacy between nirmatrelvir and repurposed compounds fluvoxamine and amodiaquine
L. Lopez Quezada, F. Mba Medie, E. P. Gabriel, R. J. Luu, L. D. Rubio, T. J. Mulhern, J. T. Borenstein, C. R. Fisher, A. L. Gard
This study evaluates the antiviral efficacy of nirmatrelvir and repurposed drugs against SARS-CoV-2 using a human airway microphysiological system, showing discrepancies with prior in vitro results.
bioRxiv · Jun 27, 2023 · PreprintBioengineering